Literature DB >> 29055005

Induction of Systemic Autoimmunity by a Xenobiotic Requires Endosomal TLR Trafficking and Signaling from the Late Endosome and Endolysosome but Not Type I IFN.

K Michael Pollard1, Gabriela M Escalante2, Hua Huang3, Katarina M Haraldsson3, Per Hultman4, Joseph M Christy2, Rahul D Pawar2, Jessica M Mayeux2, Rosana Gonzalez-Quintial3, Roberto Baccala3, Bruce Beutler5, Argyrios N Theofilopoulos3, Dwight H Kono3.   

Abstract

Type I IFN and nucleic acid-sensing TLRs are both strongly implicated in the pathogenesis of lupus, with most patients expressing IFN-induced genes in peripheral blood cells and with TLRs promoting type I IFNs and autoreactive B cells. About a third of systemic lupus erythematosus patients, however, lack the IFN signature, suggesting the possibility of type I IFN-independent mechanisms. In this study, we examined the role of type I IFN and TLR trafficking and signaling in xenobiotic systemic mercury-induced autoimmunity (HgIA). Strikingly, autoantibody production in HgIA was not dependent on the type I IFN receptor even in NZB mice that require type I IFN signaling for spontaneous disease, but was dependent on the endosomal TLR transporter UNC93B1 and the endosomal proton transporter, solute carrier family 15, member 4. HgIA also required the adaptor protein-3 complex, which transports TLRs from the early endosome to the late endolysosomal compartments. Examination of TLR signaling pathways implicated the canonical NF-κB pathway and the proinflammatory cytokine IL-6 in autoantibody production, but not IFN regulatory factor 7. These findings identify HgIA as a novel type I IFN-independent model of systemic autoimmunity and implicate TLR-mediated NF-κB proinflammatory signaling from the late endocytic pathway compartments in autoantibody generation.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29055005      PMCID: PMC5698107          DOI: 10.4049/jimmunol.1700332

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  96 in total

1.  Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice.

Authors:  Déborah Braun; Pedro Geraldes; Jocelyne Demengeot
Journal:  J Autoimmun       Date:  2003-02       Impact factor: 7.094

2.  Efficient T cell activation via a Toll-Interleukin 1 Receptor-independent pathway.

Authors:  Edith Janssen; Koichi Tabeta; Michael J Barnes; Sophie Rutschmann; Sara McBride; Keith S Bahjat; Stephen P Schoenberger; Argyrios N Theofilopoulos; Bruce Beutler; Kasper Hoebe
Journal:  Immunity       Date:  2006-06       Impact factor: 31.745

3.  Resistance to xenobiotic-induced autoimmunity maps to chromosome 1.

Authors:  D H Kono; M S Park; A Szydlik; K M Haraldsson; J D Kuan; D L Pearson; P Hultman; K M Pollard
Journal:  J Immunol       Date:  2001-08-15       Impact factor: 5.422

Review 4.  Plasmacytoid dendritic cells: recent progress and open questions.

Authors:  Boris Reizis; Anna Bunin; Hiyaa S Ghosh; Kanako L Lewis; Vanja Sisirak
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

5.  Costimulation requirements of induced murine systemic autoimmune disease.

Authors:  K Michael Pollard; Marc Arnush; Per Hultman; Dwight H Kono
Journal:  J Immunol       Date:  2004-11-01       Impact factor: 5.422

6.  Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice.

Authors:  Andreas Schwarting; Kathrin Paul; Stefan Tschirner; Julia Menke; Torsten Hansen; Walburgis Brenner; Vicki Rubin Kelley; Manfred Relle; Peter R Galle
Journal:  J Am Soc Nephrol       Date:  2005-10-12       Impact factor: 10.121

7.  Role of nucleic acid-sensing TLRs in diverse autoantibody specificities and anti-nuclear antibody-producing B cells.

Authors:  Yi Ting Koh; John C Scatizzi; Jennifer D Gahan; Brian R Lawson; Roberto Baccala; K Michael Pollard; Bruce A Beutler; Argyrios N Theofilopoulos; Dwight H Kono
Journal:  J Immunol       Date:  2013-04-15       Impact factor: 5.422

Review 8.  Autoimmunity through cytokine-induced dendritic cell activation.

Authors:  Jacques Banchereau; Virginia Pascual; A Karolina Palucka
Journal:  Immunity       Date:  2004-05       Impact factor: 31.745

9.  Noncanonical autophagy is required for type I interferon secretion in response to DNA-immune complexes.

Authors:  Jill Henault; Jennifer Martinez; Douglas R Green; Miguel A Sanjuan; Jeffrey M Riggs; Jane Tian; Payal Mehta; Lorraine Clarke; Miwa Sasai; Eicke Latz; Melanie M Brinkmann; Akiko Iwasaki; Anthony J Coyle; Roland Kolbeck
Journal:  Immunity       Date:  2012-12-06       Impact factor: 31.745

10.  Type I IFN protects against murine lupus.

Authors:  Jonathan D Hron; Stanford L Peng
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

View more
  6 in total

1.  TLR7-Mediated Lupus Nephritis Is Independent of Type I IFN Signaling.

Authors:  Sonya J Wolf; Jonathan Theros; Tammi J Reed; Jianhua Liu; Irina L Grigorova; Giovanny Martínez-Colón; Chaim O Jacob; Jeffrey B Hodgin; J Michelle Kahlenberg
Journal:  J Immunol       Date:  2018-06-08       Impact factor: 5.422

Review 2.  Mercury-induced inflammation and autoimmunity.

Authors:  K Michael Pollard; David M Cauvi; Christopher B Toomey; Per Hultman; Dwight H Kono
Journal:  Biochim Biophys Acta Gen Subj       Date:  2019-02-10       Impact factor: 3.770

Review 3.  Common innate pathways to autoimmune disease.

Authors:  David Langan; Noel R Rose; Kamal D Moudgil
Journal:  Clin Immunol       Date:  2020-02-10       Impact factor: 3.969

4.  Environmental Xenobiotic Exposure and Autoimmunity.

Authors:  K Michael Pollard; Joseph M Christy; David M Cauvi; Dwight H Kono
Journal:  Curr Opin Toxicol       Date:  2017-11-21

5.  Cross-Disease Innate Gene Signature: Emerging Diversity and Abundance in RA Comparing to SLE and SSc.

Authors:  Anna Petrackova; Pavel Horak; Martin Radvansky; Martina Skacelova; Regina Fillerova; Milos Kudelka; Andrea Smrzova; Frantisek Mrazek; Eva Kriegova
Journal:  J Immunol Res       Date:  2019-07-16       Impact factor: 4.818

6.  TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7-9.

Authors:  Leonhard X Heinz; JangEun Lee; Utkarsh Kapoor; Felix Kartnig; Vitaly Sedlyarov; Konstantinos Papakostas; Adrian César-Razquin; Patrick Essletzbichler; Ulrich Goldmann; Adrijana Stefanovic; Johannes W Bigenzahn; Stefania Scorzoni; Mattia D Pizzagalli; Ariel Bensimon; André C Müller; F James King; Jun Li; Enrico Girardi; M Lamine Mbow; Charles E Whitehurst; Manuele Rebsamen; Giulio Superti-Furga
Journal:  Nature       Date:  2020-05-13       Impact factor: 49.962

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.